$ALMS

Hardiman Roy C. sold $71K of ALMS

Hardiman Roy C. (Chief Business & Strategy Ofcr) sold 2,692 shares of ALUMIS INC. (ALMS) at $26.37 on 2026-08-03.

Original reporting
SEC EDGAR · Hardiman Roy C.
Published Aug 5, 2026, 10:44 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 11:08 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ALMS
Neutral
low confidence
Mentioned
$ALMS
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALMSNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (shares, price, total value, and post-transaction holdings) by an officer, with no pre-arranged 10b5-1 plan stated.

02

Market read

Traders may note insider selling as a minor sentiment datapoint, but there is no accompanying company-specific catalyst.

03

What to watch

The filing does not disclose intent, tax context, or whether other insiders are trading; without follow-on buys/sales patterns, signal quality is low.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-05, transaction dated 2026-08-03

Background

The article is an SEC Form 4 insider transaction disclosure for ALUMIS INC. (ALMS).

Company-level read

Ticker impact

$ALMSNeutralLow confidence
Context

ALMS insider Form 4 shows officer Hardiman Roy C. sold 2,692 shares for about $70,988 at $26.37 on 2026-08-03.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

Form 4 insider sales are common and often non-informational; the filing lacks context on motives, and the transaction size is modest relative to typical market moves.

Market effects

No clear sector read-through from a single insider sale.

None indicated.

None indicated.

Counterpoint

The absence of a stated 10b5-1 plan does not necessarily imply negative information; insiders may sell for diversification, taxes, or planned liquidity needs.

Key entities

  • ALUMIS INC.

    Company whose insider transaction is disclosed on Form 4.

  • Hardiman Roy C.

    Chief Business & Strategy Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALMSMedAI 8/10

Alumis Phase 2b LUMUS Trial Misses Endpoints; Stock Plunges

Alumis Inc. (ALMS) reported Phase 2b LUMUS trial results for Envudeucitinib in SLE, missing primary and secondary endpoints overall but showing promise in a subset of patients with high interferon gene signature. The drug demonstrated improvements in several measures in this subgroup and was well tolerated. The company plans to discuss Phase 3 development with regulators. ALMS stock fell over 55% in pre-market trading.

$ALMSHighAI 8/10

Why is Alumis stock collapsing today?

Alumis stock fell 54.2% in pre-market trading after its Phase 2b LUMUS trial for envudeucitinib in systemic lupus erythematosus missed primary and secondary endpoints. A subgroup of patients showed positive responses, but the overall trial population was under-represented. The company plans to discuss a Phase 3 program with regulators. The Nasdaq, S&P 500, and Dow Jones also declined, exacerbating the sell-off.

$ALMSHighAI 8/10

Alumis stock tumbles 55% after lupus drug trial misses goals

Alumis Inc. (ALMS) shares dropped 55% after its Phase 2b LUMUS trial for envudeucitinib in lupus failed primary and secondary endpoints. The trial enrolled 408 patients but showed improvements only in a subgroup with high interferon gene signature (IFNGS-high). The drug was well-tolerated, and the company plans to discuss Phase 3 development for this subgroup with regulators. Alumis remains on track to submit a New Drug Application for psoriasis in Q4 2026.

$ALMSLowAI 8/10

Alumis Inc.: Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)

Alumis Inc. (ALMS) reported that its Phase 2b LUMUS trial of envudeucitinib for systemic lupus erythematosus (SLE) did not meet primary and secondary endpoints in the overall population. However, a prespecified subgroup of patients with high interferon gene signature (IFNGS-high) showed robust responses. The company plans to discuss Phase 3 development with regulators. Envudeucitinib was well tolerated. Alumis remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psor